Positive Earnings Report Bodes Well for Dialysis Provider

DaVita is being propped up by support from its 30-day moving average

by Research Dept.

Published on May 20, 2020 at 2:40 PM

Kidney dialysis provider DaVita Inc (NYSE:DVA) has been on a long-term climb on the charts, and following its mid-March pullback, has broken back above its year-to-date breakeven mark, as well as a trendline connecting lower highs since February. The shares are also seeing support at the 30-day moving average, following a positive earnings reaction on May 6. With this support in place, now is the perfect time for bulls to jump aboard DVA.

Daily DVA WKEND

 

There remains plenty of analyst pessimism surrounding the stock, with five of eight covering firms sporting a tepid "hold" recommendation. If this heightened pessimism were to unwind, it could mean an even larger surge for DaVita stock in the near future.

Shorts look to be in covering mode, with 5.5 million shares now sold short. This accounts for 4.6% of the stock’s total available float, or just over three days’ worth of pent-up buying power.

Lastly, the security’s Schaeffer’s Volatility Index (SVI) of 39% sits in the 25th percentile of its annual range, meaning options players are pricing in relatively low volatility expectations at the moment.

Subscribers to Schaeffer's Weekend Trader options recommendation service received this DVA commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters. Learn more about why Weekend Trader is one of our most popular options trading services.


A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Wall Street Roars Higher Amid Civil Unrest
Investors weighed a mixed bag of jobs data
AstraZeneca Stock Flat Despite COVID-19 Vaccine News
AstraZeneca saw a rise in capacity for its COVID-19 vaccine candidate
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.